Published in Clin Endocrinol (Oxf) on September 01, 2006
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol (2014) 4.75
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol (2009) 1.96
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
Thyroid cancer gender disparity. Future Oncol (2010) 1.36
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab (2015) 1.24
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 1.23
Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res (2012) 1.19
BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg (2014) 1.00
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol (2012) 1.00
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery (2012) 0.99
Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg (2010) 0.95
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery (2012) 0.94
The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies. J Oncol (2011) 0.88
Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population. Thyroid (2013) 0.87
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir (2010) 0.85
Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. J Korean Med Sci (2014) 0.85
The association between BRAF (V600E) mutation and pathological features in PTC. Eur Arch Otorhinolaryngol (2014) 0.84
Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital. J Thyroid Res (2011) 0.84
The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis. Int J Clin Exp Med (2015) 0.84
Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today (2010) 0.83
Occult thyroid carcinoma. Acta Otorhinolaryngol Ital (2009) 0.83
A closer look at papillary thyroid carcinoma. Endocrinol Metab (Seoul) (2015) 0.82
Translational research in endocrine surgery. Surg Oncol Clin N Am (2013) 0.81
RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence. Am J Cancer Res (2014) 0.79
Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease. J Clin Endocrinol Metab (2014) 0.79
BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol (2012) 0.79
Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis? Int J Clin Oncol (2014) 0.79
The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. Gland Surg (2013) 0.78
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma. Endocrinol Metab (Seoul) (2016) 0.78
Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J (2015) 0.77
Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules. PLoS One (2013) 0.77
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg (2016) 0.77
The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One (2015) 0.77
Clinicopathologic features of familial nonmedullary thyroid carcinoma. Chin Med J (Engl) (2015) 0.77
Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder. J Korean Med Sci (2011) 0.77
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. Oncologist (2013) 0.76
BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg (2016) 0.76
TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci Rep (2017) 0.75
Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One (2014) 0.75
A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect (2017) 0.75
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol (2006) 2.92
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell (2012) 2.21
Diagnostic accuracy of ultrasound and 18-F-FDG PET or PET/CT for patients with suspected recurrent papillary thyroid carcinoma. Ultrasound Med Biol (2010) 2.04
Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) (2004) 1.96
Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf) (2005) 1.95
Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat (2007) 1.92
Echinococcosis of the liver. Abdom Imaging (2008) 1.88
Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) (2004) 1.87
The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab (2011) 1.74
Zinc deficiency may be a cause of burning mouth syndrome as zinc replacement therapy has therapeutic effects. J Oral Pathol Med (2010) 1.55
Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J Control Release (2010) 1.51
MR imaging of reperfused myocardial infarction: comparison of necrosis-specific and intravascular contrast agents in a cat model. Radiology (2003) 1.47
[Gene expression profiling using oligonucleotide microarray in atrophic gastritis and intestinal metaplasia]. Korean J Gastroenterol (2007) 1.47
Experience with meconium peritonitis. J Pediatr Surg (2007) 1.45
Effects of the anti-sepsis drug, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD-712), on mortality, inflammation, and organ injuries in rodent sepsis models. Arch Pharm Res (2011) 1.44
Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.44
Cell cycle and developmental regulations of replication factors in mouse embryonic stem cells. J Biol Chem (2005) 1.43
Expression profiling and subtype-specific expression of stomach cancer. Cancer Res (2003) 1.43
A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl (2008) 1.43
Mesenchymal neoplasms of the major salivary glands: clinicopathological features of 18 cases. Eur Arch Otorhinolaryngol (2007) 1.41
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
Basal cell adenocarcinoma of the salivary gland: a morphological and immunohistochemical comparison with basal cell adenoma with and without capsular invasion. Diagn Pathol (2013) 1.39
18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas. Clin Nucl Med (2017) 1.39
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. Mol Cell (2010) 1.35
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) (2005) 1.35
Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol (2008) 1.30
Invasive colorectal micropapillary carcinoma: an aggressive variant of adenocarcinoma. Hum Pathol (2006) 1.30
Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring. Bioorg Med Chem (2004) 1.29
18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope (2005) 1.28
Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) (2009) 1.27
Metastatic carcinomas to the oral cavity and oropharynx. Korean J Pathol (2012) 1.27
Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev (2009) 1.25
Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) (2004) 1.24
Solitary fibrous tumor of the parapharyngeal space: MR imaging findings. AJNR Am J Neuroradiol (2002) 1.24
Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.23
Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer (2013) 1.22
Embolization versus surgical resection of pulmonary sequestration: clinical experiences with a thoracoscopic approach. J Pediatr Surg (2012) 1.21
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release (2007) 1.18
Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One (2008) 1.17
Heparin-coated gold nanoparticles for liver-specific CT imaging. Chemistry (2009) 1.17
Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res (2012) 1.17
Papillary thyroid carcinoma arising from a thyroglossal duct cyst: a single institution experience. Endocr J (2013) 1.16
Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol (2013) 1.16
The surgical experience for retroperitoneal, mesenteric and omental cyst in children. J Korean Surg Soc (2012) 1.15
Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol (2008) 1.15
Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett (2009) 1.13
FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol Cell (2013) 1.11
Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol (2007) 1.11
18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab (2007) 1.11
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10